Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

New Researches about Combinatorial Therapeutic Regimen on Cancer Treatment

Author(s): Xinjia He, Qiaqia He*, Lihua Wang and Xiaofei He

Volume 16, Issue 2, 2020

Page: [97 - 109] Pages: 13

DOI: 10.2174/1573394715666190906125014

Abstract

Cancer is a refractory disease, which brings physical, mental and economic sufferings on patients and their families. The activation of oncogenes and/or the deletion of tumor repressors result in uncontrolled tumor survival and proliferation. Therapeutic resistance and cancer recurrence are common issues during the course of clinical treatment. Since each single treatment can’t eradicate tumor cells completely, the development of combinatorial therapeutic regimen is in the spotlight for several decades. Combinatorial therapeutic regimen, a treatment modality that combines two or more therapeutic agents, targets key pathways in a characteristically synergistic or an additive manner. It aims to improve the efficacy and magnitude of therapeutic responses and reduce the likelihood of acquired resistance by using optimal drug dose with tolerable side effect. Currently, the combinatorial therapeutic regimen not only includes various chemicals, but also diverse therapeutic modalities which affected DNA damage repair, protein localization and degradation, post-translational modification, cell metabolism and apoptosis, as well as immune response.

Keywords: Cancer treatment, combinatorial therapeutic regime, strain sensitivity, breast cancer, DNA damage repair, posttranslational modification.

« Previous Next »
Graphical Abstract

[1]
Shailubhai K. Use of a combinational therapy of lsd1 inhibitors with cdk2 inhibitors in the treatment of cancer United States patent application US Patent 15/962,492,. 2018.
[2]
World Health Organization. Available from: . http://www.who.int/ cancer/en/
[3]
Stewart BW, Wild CP. World cancer report 2014. Health . 2017.Available from: https://www.who.int/cancer/publications/WRC_ 2014/en/
[4]
Yan J, Sun H, Li J, Qi W, Wang H. A theranostic plaster combining photothermal therapy and photodynamic therapy based on chlorin e6/gold nanorods (Ce6/Au nrs) composite. Colloids Surf A Physicochem Eng Asp 2018; 537: 460-6.
[http://dx.doi.org/10.1016/j.colsurfa.2017.10.051]
[5]
Silmon S. 2018.in Review: New cancer drug approvals Available from: https://www.cancer.org/latest-news/2018-in-review-new-cancer-drug-approvals.html.2018
[6]
Sun J, Yin M, Zhu S, et al. Ultrasound-mediated destruction of oxygen and paclitaxel loaded lipid microbubbles for combination therapy in hypoxic ovarian cancer cells. Ultrason Sonochem 2016; 28: 319-26.
[http://dx.doi.org/10.1016/j.ultsonch.2015.08.009] [PMID: 26384914]
[7]
Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. Expert Opin Investig Drugs 2016; 25(5): 597-611.
[http://dx.doi.org/10.1517/13543784.2016.1156857] [PMID: 26899229]
[8]
Ji RC. Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis. Cancer Lett 2014; 346(1): 6-16.
[http://dx.doi.org/10.1016/j.canlet.2013.12.001] [PMID: 24333723]
[9]
Brenneisen P, Reichert AS. Nanotherapy and reactive oxygen species (ROS) in cancer: A novel perspective. Antioxidants 2018; 7(2): E31
[http://dx.doi.org/10.3390/antiox7020031] [PMID: 29470419]
[10]
Yang S, Tang Z, Hu C, et al. Selectively potentiating hypoxia levels by combretastatin A4 nanomedicine: Toward highly enhanced hypoxia-activated prodrug tirapazamine therapy for metastatic tumors. Adv Mater 2019; 31(11): e1805955
[http://dx.doi.org/10.1002/adma.201805955] [PMID: 30680816]
[11]
Du W, Goldstein R, Jiang Y, et al. Effective combination therapies for B-cell lymphoma predicted by a virtual disease model. Cancer Res 2017; 77(8): 1818-30.
[http://dx.doi.org/10.1158/0008-5472.CAN-16-0476] [PMID: 28130226]
[12]
Elmi A, Makvandi M, Weng CC, et al. Cell-proliferation imaging for monitoring response to CDK4/6 inhibition combined with endocrine-therapy in breast cancer: Comparison of [(18)F]FLT and [(18)F]ISO-1 PET/CT. Clin Cancer Res 2019; 25(10): 3063-73.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-2769] [PMID: 30692100]
[13]
Li J, Qu X, Tian J, Zhang JT, Cheng JX. Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation. PLoS One 2018; 13(2): e0193318
[http://dx.doi.org/10.1371/journal.pone.0193318] [PMID: 29489864]
[14]
Qin SY, Cheng YJ, Lei Q, Zhang AQ, Zhang XZ. Combinational strategy for high-performance cancer chemotherapy. Biomaterials 2018; 171: 178-97.
[http://dx.doi.org/10.1016/j.biomaterials.2018.04.027] [PMID: 29698868]
[15]
Li Y, Gao X, Yu Z, et al. Reversing multidrug resistance by multiplexed gene silencing for enhanced breast cancer chemotherapy. ACS Appl Mater Interfaces 2018; 10(18): 15461-6.
[http://dx.doi.org/10.1021/acsami.8b02800] [PMID: 29663807]
[16]
Xue G, Hemmings BA. AGC kinases in cancer metastasis, immune checkpoint regulation and drug resistance. Semin Cancer Biol 2018; 48: iii-v.
[http://dx.doi.org/10.1016/j.semcancer.2018.01.013] [PMID: 29429565]
[17]
Zhao H, Li Y, Wei D, Luo H. The application of nanoparticle-based drug delivery systems in checkpoint blockade cancer immunotherapy. J Immunol Res 2018; 2018: 3673295
[http://dx.doi.org/10.1155/2018/3673295] [PMID: 30406152]
[18]
Cruickshanks N, Zhang Y, Hine S, et al. Discovery and therapeutic exploitation of mechanisms of resistance to MET inhibitors in glioblastoma. Clin Cancer Res 2019; 25(2): 663-73.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-0926] [PMID: 30201763]
[19]
Chen J, Li X, Zhao X, et al. Doxorubicin-conjugated pH-responsive gold nanorods for combined photothermal therapy and chemotherapy of cancer. Bioact Mater 2018; 3(3): 347-54.
[http://dx.doi.org/10.1016/j.bioactmat.2018.05.003] [PMID: 29992194]
[20]
Kang S, Shin W, Kang K, et al. Revisiting of Pd nanoparticles in cancer treatment: All-round excellence of porous Pd nanoplates in gene-thermo combinational therapy. ACS Appl Mater Interfaces 2018; 10(16): 13819-28.
[http://dx.doi.org/10.1021/acsami.8b01000] [PMID: 29608263]
[21]
Li X, Zhao X, Pardhi D, et al. Folic acid modified cell membrane capsules encapsulating doxorubicin and indocyanine green for highly effective combinational therapy in vivo. Acta Biomater 2018; 74: 374-84.
[http://dx.doi.org/10.1016/j.actbio.2018.05.006] [PMID: 29734009]
[22]
Lee BY, Clemens DL, Silva A, et al. Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time. Nat Commun 2017; 8: 14183.
[http://dx.doi.org/10.1038/ncomms14183] [PMID: 28117835]
[23]
Liao L, Liu J, Dreaden EC, et al. A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. J Am Chem Soc 2014; 136(16): 5896-9.
[http://dx.doi.org/10.1021/ja502011g] [PMID: 24724706]
[24]
Lowe KL, Mackall CL, Norry E, Amado R, Jakobsen BK, Binder G. Fludarabine and neurotoxicity in engineered T-cell therapy. Gene Ther 2018; 25(3): 176-91.
[http://dx.doi.org/10.1038/s41434-018-0019-6] [PMID: 29789639]
[25]
Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 2009; 58(3): 317-24.
[http://dx.doi.org/10.1007/s00262-008-0576-4] [PMID: 18704409]
[26]
Chiou YS, Li S, Ho CT, Pan MH. Prevention of breast cancer by natural phytochemicals: Focusing on molecular targets and combinational strategy. Mol Nutr Food Res 2018; 62(23): e1800392
[http://dx.doi.org/10.1002/mnfr.201800392] [PMID: 30168668]
[27]
Grabosch S, Zeng F, Ma T, et al. Chemo-induced biology of PD-L1 and in vivo combination immune therapy for ovarian cancer. Gynecol Oncol 2016; 141: 86.
[http://dx.doi.org/10.1016/j.ygyno.2016.04.239]
[28]
Zamarin D, Holmgaard RB, Ricca J, et al. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun 2017; 8: 14340.
[http://dx.doi.org/10.1038/ncomms14340] [PMID: 28194010]
[29]
Xu X, Ho W, Zhang X, Bertrand N, Farokhzad O. Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol Med 2015; 21(4): 223-32.
[http://dx.doi.org/10.1016/j.molmed.2015.01.001] [PMID: 25656384]
[30]
Liu R, Xiao W, Hu C, Xie R, Gao H. Theranostic size-reducible and no donor conjugated gold nanocluster fabricated hyaluronic acid nanoparticle with optimal size for combinational treatment of breast cancer and lung metastasis. J Control Release 2018; 278: 127-39.
[http://dx.doi.org/10.1016/j.jconrel.2018.04.005] [PMID: 29630985]
[31]
Parmar MB, Meenakshi Sundaram DN, K C RB, et al. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells. Acta Biomater 2018; 66: 294-309.
[http://dx.doi.org/10.1016/j.actbio.2017.11.036] [PMID: 29183848]
[32]
Sengupta S, Eavarone D, Capila I, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005; 436(7050): 568-72.
[http://dx.doi.org/10.1038/nature03794] [PMID: 16049491]
[33]
Hu CM, Fang RH, Wang KC, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 2015; 526(7571): 118-21.
[http://dx.doi.org/10.1038/nature15373] [PMID: 26374997]
[34]
Mao Z, Cartier R, Hohl A, et al. Cells as factories for humanized encapsulation. Nano Lett 2011; 11(5): 2152-6.
[http://dx.doi.org/10.1021/nl200801n] [PMID: 21486057]
[35]
He C, Liu D, Lin W. Self-assembled core-shell nanoparticles for combined chemotherapy and photodynamic therapy of resistant head and neck cancers. ACS Nano 2015; 9(1): 991-1003.
[http://dx.doi.org/10.1021/nn506963h] [PMID: 25559017]
[36]
Yu F, Zhang F, Tang L, et al. Redox-responsive dual chemophotothermal therapeutic nanomedicine for imaging-guided combinational therapy. J Mater Chem B Mater Biol Med 2018; 6(33): 5362-7.
[http://dx.doi.org/10.1039/C8TB01360H] [PMID: 30931124]
[37]
Tang W, Yang Z, Wang S, et al. Organic semiconducting photoacoustic nanodroplets for laser-activatable ultrasound imaging and combinational cancer therapy. ACS Nano 2018; 12(3): 2610-22.
[http://dx.doi.org/10.1021/acsnano.7b08628] [PMID: 29451774]
[38]
Zhang Y, Chu W, Foroushani AD, et al. New gold nanostructures for sensor applications: A review. Materials (Basel) 2014; 7(7): 5169-201.
[http://dx.doi.org/10.3390/ma7075169] [PMID: 28788124]
[39]
Moon HK, Lee SH, Choi HC. In vivo near-infrared mediated tumor destruction by photothermal effect of carbon nanotubes. ACS Nano 2009; 3(11): 3707-13.
[http://dx.doi.org/10.1021/nn900904h] [PMID: 19877694]
[40]
Chen MC, Lin ZW, Ling MH. Near-infrared light-activatable microneedle system for treating superficial tumors by combination of chemotherapy and photothermal therapy. ACS Nano 2016; 10(1): 93-101.
[http://dx.doi.org/10.1021/acsnano.5b05043] [PMID: 26592739]
[41]
Chen WH, Luo GF, Lei Q, et al. Overcoming the heat endurance of tumor cells by interfering with the anaerobic glycolysis metabolism for improved photothermal therapy. ACS Nano 2017; 11(2): 1419-31.
[http://dx.doi.org/10.1021/acsnano.6b06658] [PMID: 28107631]
[42]
Xiang H, Xue F, Yi T, Tham HP, Liu JG, Zhao Y. Cu2- xS nanocrystals cross-linked with chlorin e6-functionalized polyethylenimine for synergistic photodynamic and photothermal therapy of cancer. ACS Appl Mater Interfaces 2018; 10(19): 16344-51.
[http://dx.doi.org/10.1021/acsami.8b04779] [PMID: 29697957]
[43]
Zhang D, Wu M, Zeng Y, et al. Chlorin e6 conjugated poly(dopamine) nanospheres as PDT/PTT dual-modal therapeutic agents for enhanced cancer therapy. ACS Appl Mater Interfaces 2015; 7(15): 8176-87.
[http://dx.doi.org/10.1021/acsami.5b01027] [PMID: 25837008]
[44]
Zhao P, Zheng M, Yue C, et al. Improving drug accumulation and photothermal efficacy in tumor depending on size of ICG loaded lipid-polymer nanoparticles. Biomaterials 2014; 35(23): 6037-46.
[http://dx.doi.org/10.1016/j.biomaterials.2014.04.019] [PMID: 24776486]
[45]
Maruyama T, Akutsu Y, Suganami A, et al. Treatment of near-infrared photodynamic therapy using a liposomally formulated indocyanine green derivative for squamous cell carcinoma. PLoS One 2015; 10(4): e0122849
[http://dx.doi.org/10.1371/journal.pone.0122849] [PMID: 25850029]
[46]
Yan F, Wu H, Liu H, et al. Molecular imaging-guided photothermal/photodynamic therapy against tumor by iRGD-modified indocyanine green nanoparticles. J Control Release 2016; 224: 217-28.
[http://dx.doi.org/10.1016/j.jconrel.2015.12.050] [PMID: 26739551]
[47]
Kumar P, Srivastava R. IR 820 dye encapsulated in polycaprolactone glycol chitosan: Poloxamer blend nanoparticles for photo immunotherapy for breast cancer. Mater Sci Eng C 2015; 57: 321-7.
[http://dx.doi.org/10.1016/j.msec.2015.08.006] [PMID: 26354271]
[48]
Zhao Z, Shi S, Huang Y, Tang S, Chen X. Simultaneous photodynamic and photothermal therapy using photosensitizer-functionalized Pd nanosheets by single continuous wave laser. ACS Appl Mater Interfaces 2014; 6(11): 8878-85.
[http://dx.doi.org/10.1021/am501608c] [PMID: 24801639]
[49]
Cecchini M, Walther Z, Sklar JL, et al. Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes. Lancet Oncol 2018; 19(1): 23-4.
[http://dx.doi.org/10.1016/S1470-2045(17)30916-6] [PMID: 29304353]
[50]
Langdon CG, Platt JT, Means RE, et al. Combinatorial screening of pancreatic adenocarcinoma reveals sensitivity to drug combinations including bromodomain inhibitor plus neddylation inhibitor. Mol Cancer Ther 2017; 16(6): 1041-53.
[http://dx.doi.org/10.1158/1535-7163.MCT-16-0794] [PMID: 28292938]
[51]
Noh J, Jung E, Lee J, Hyun H, Hong S, Lee D. Engineered polymeric micelles for combinational oxidation anticancer therapy through concurrent HO-1 inhibition and ROS generation. Biomacromolecules 2019; 20(2): 1109-17.
[http://dx.doi.org/10.1021/acs.biomac.8b01802] [PMID: 30605610]
[52]
National Cancer Institute. 2019. Available from: https://www.cancer.gov/types/common-cancers
[53]
Olov N, Bagheri-Khoulenjani S, Mirzadeh H. Combinational drug delivery using nanocarriers for breast cancer treatments: A review. J Biomed Mater Res A 2018; 106(8): 2272-83.
[http://dx.doi.org/10.1002/jbm.a.36410] [PMID: 29577607]
[54]
Chakraborty A, Hatzis C, DiGiovanna MP. Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease. Breast Cancer Res Treat 2017; 163(1): 37-50.
[http://dx.doi.org/10.1007/s10549-017-4169-9] [PMID: 28236033]
[55]
Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010; 28(8): 1301-7.
[http://dx.doi.org/10.1200/JCO.2009.25.8707] [PMID: 20142587]
[56]
Carboni JM, Wittman M, Yang Z, et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 2009; 8(12): 3341-9.
[http://dx.doi.org/10.1158/1535-7163.MCT-09-0499] [PMID: 19996272]
[57]
Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010; 11(2): 129-35.
[http://dx.doi.org/10.1016/S1470-2045(09)70354-7] [PMID: 20036194]
[58]
Jhan JR, Andrechek ER. Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis. Oncogene 2017; 36(25): 3553-61.
[http://dx.doi.org/10.1038/onc.2016.503] [PMID: 28135251]
[59]
Khaki-Khatibi F, Ghorbani M, Sabzichi M, Ramezani F, Mohammadian J. Adjuvant therapy with stattic enriches the anti-proliferative effect of doxorubicin in human ZR-75-1 breast cancer cells via arresting cell cycle and inducing apoptosis. Biomed Pharmacother 2019; 109: 1240-8.
[http://dx.doi.org/10.1016/j.biopha.2018.10.183] [PMID: 30551374]
[60]
Nezami M, Hager S, Taguchi J. Biological modulation of parp inhibition in triple negative breast cancer, a combinational approach implementing multitargeted epigenetic therapy (Mtet) with Parp inhibition, in advanced breast cancer: A Case Study. J Cancer Ther 2018; 09(09): 729-39.
[http://dx.doi.org/10.4236/jct.2018.99060]
[61]
Zhang X, Li Y, Wei M, Liu C, Yang J. Cetuximab-modified silica nanoparticle loaded with ICG for tumor-targeted combinational therapy of breast cancer. Drug Deliv 2019; 26(1): 129-36.
[http://dx.doi.org/10.1080/10717544.2018.1564403] [PMID: 30798640]
[62]
Shi M, Zhang J, Li J. Fan Y, Wang J, Sun W, et al. Polydopamine-coated magnetic mesoporous silica nanoparticles for multimodal cancer theranostics. J Mater Chem B Mater Biol Med 2019; 7(3): 368-72.
[http://dx.doi.org/10.1039/C8TB03021A]
[63]
Wu T, Qiao Q, Qin X, Zhang D, Zhang Z. Immunostimulatory cytokine and doxorubicin co-loaded nanovesicles for cancer immunochemotherapy. Nanomedicine (Lond) 2019; 18: 66-77.
[http://dx.doi.org/10.1016/j.nano.2019.02.008] [PMID: 30831276]
[64]
Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 1997; 242(1): 27-33.
[http://dx.doi.org/10.1046/j.1365-2796.1997.00170.x] [PMID: 9260563]
[65]
Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61(7): 1303-13.
[http://dx.doi.org/10.1016/0092-8674(90)90694-A] [PMID: 1694723]
[66]
Idowu MO, Kmieciak M, Dumur C, et al. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 2012; 43(3): 364-73.
[http://dx.doi.org/10.1016/j.humpath.2011.05.005] [PMID: 21835433]
[67]
Xie K, Fidler IJ. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev 1998; 17(1): 55-75.
[http://dx.doi.org/10.1023/A:1005956721457] [PMID: 9544423]
[68]
Tan Y, Zhu Y, Wen L, et al. Mitochondria-responsive drug release along with heat shock mediated by multifunctional glycolipid micelles for precise cancer chemo-phototherapy. Theranostics 2019; 9(3): 691-707.
[http://dx.doi.org/10.7150/thno.31022] [PMID: 30809302]
[69]
American Cancer Society. 2019.Available from: https://www. cancer.org/cancer/ovarian-cancer/about/key-statistics.html
[70]
Watatani M, Ueda K, Daito K, et al. Clinical experience of weekly paclitaxel-based treatment as preoperative chemotherapy for patients with primary breast cancer. Breast Cancer 2004; 11(2): 187-93.
[http://dx.doi.org/10.1007/BF02968300] [PMID: 15550866]
[71]
Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31(15): 1869-83.
[http://dx.doi.org/10.1038/onc.2011.384] [PMID: 21892204]
[72]
Ayyagari VN, Hsieh TJ, Diaz-Sylvester PL, Brard L. Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines. BMC Cancer 2017; 17(1): 49.
[http://dx.doi.org/10.1186/s12885-016-3034-2] [PMID: 28086831]
[73]
Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146(5): 1029-39.
[PMID: 7538264]
[74]
Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32(13): 1302-8.
[http://dx.doi.org/10.1200/JCO.2013.51.4489] [PMID: 24637997]
[75]
Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014; 15(11): 1207-14.
[http://dx.doi.org/10.1016/S1470-2045(14)70391-2] [PMID: 25218906]
[76]
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366(15): 1382-92.
[http://dx.doi.org/10.1056/NEJMoa1105535] [PMID: 22452356]
[77]
Oza AM, Cibula D, Benzaquen AO, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2015; 16(1): 87-97.
[http://dx.doi.org/10.1016/S1470-2045(14)71135-0] [PMID: 25481791]
[78]
Pfisterer J, Plante M, Vergote I, et al. AGO-OVAR NCIC CTG EORTC GCG.. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24(29): 4699-707.
[http://dx.doi.org/10.1200/JCO.2006.06.0913] [PMID: 16966687]
[79]
Sarkar S, Faller DV. T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells. Oligonucleotides 2011; 21(1): 47-53.
[http://dx.doi.org/10.1089/oli.2010.0259] [PMID: 21281128]
[80]
Lapinska K, Housman G, Byler S, et al. The effects of histone deacetylase inhibitor and calpain inhibitor combination therapies on ovarian cancer cells. Anticancer Res 2016; 36(11): 5731-42.
[http://dx.doi.org/10.21873/anticanres.11156] [PMID: 27793894]
[81]
Chen X, Gong L, Ou R, et al. Sequential combination therapy of ovarian cancer with cisplatin and γ-secretase inhibitor MK-0752. Gynecol Oncol 2016; 140(3): 537-44.
[http://dx.doi.org/10.1016/j.ygyno.2015.12.011] [PMID: 26704638]
[82]
Shah MM, Zerlin M, Li BY, Herzog TJ, Kitajewski JK, Wright JD. The role of Notch and gamma-secretase inhibition in an ovarian cancer model. Anticancer Res 2013; 33(3): 801-8.
[PMID: 23482747]
[83]
Wang M, Ma X, Wang J, Wang L, Wang Y. Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling. Int J Oncol 2014; 44(4): 1401-9.
[http://dx.doi.org/10.3892/ijo.2014.2301] [PMID: 24535252]
[84]
Chen X, Dai X, Zou P, et al. Curcuminoid EF24 enhances the anti-tumour activity of Akt inhibitor MK-2206 through ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction in gastric cancer. Br J Pharmacol 2017; 174(10): 1131-46.
[http://dx.doi.org/10.1111/bph.13765] [PMID: 28255993]
[85]
Tseng YY, Yang TC, Wang YC, et al. Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to the brain by using drug-loaded nanofibrous membranes. Int J Nanomedicine 2017; 12: 1265-76.
[http://dx.doi.org/10.2147/IJN.S124593] [PMID: 28243088]
[86]
Suryaprakash S, Lao YH, Cho HY, et al. Engineered mesenchymal stem cell/nanomedicine spheroid as an active drug delivery platform for combinational glioblastoma therapy. Nano Lett 2019; 19(3): 1701-5.
[http://dx.doi.org/10.1021/acs.nanolett.8b04697] [PMID: 30773888]
[87]
Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54(6): 1556-60.
[PMID: 8137263]
[88]
Lee H, Han J, Shin H, Han H, Na K, Kim H. Combination of chemotherapy and photodynamic therapy for cancer treatment with sonoporation effects. J Control Release 2018; 283: 190-9.
[http://dx.doi.org/10.1016/j.jconrel.2018.06.008] [PMID: 29885415]
[89]
Biteghe FN, Davids LM. A combination of photodynamic therapy and chemotherapy displays a differential cytotoxic effect on human metastatic melanoma cells. J Photochem Photobiol B 2017; 166: 18-27.
[http://dx.doi.org/10.1016/j.jphotobiol.2016.11.004] [PMID: 27852006]
[90]
Bonelli MA, Fumarola C, La Monica S, Alfieri R. New therapeutic strategies for malignant pleural mesothelioma. Biochem Pharmacol 2017; 123: 8-18.
[http://dx.doi.org/10.1016/j.bcp.2016.07.012] [PMID: 27431778]
[91]
Zalcman G, Mazieres J, Margery J, et al. French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016; 387(10026): 1405-14.
[http://dx.doi.org/10.1016/S0140-6736(15)01238-6] [PMID: 26719230]
[92]
American Liver Foundation; 2019.Available from: . https://liver foundation.org/for-patients/about-the-liver/diseases-of-the-liver/ liver-cancer/
[93]
Choueiri TK, Motzer RJ. Systemic Therapy for metastatic renal-cell carcinoma. N Engl J Med 2017; 376(4): 354-66.
[http://dx.doi.org/10.1056/NEJMra1601333] [PMID: 28121507]
[94]
Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015; 16(15): 1473-82.
[http://dx.doi.org/10.1016/S1470-2045(15)00290-9] [PMID: 26482279]
[95]
Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008; 14(17): 5459-65.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-5270] [PMID: 18765537]
[96]
Motzer RJ, Escudier B, McDermott DF, et al. CheckMate 025 investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373(19): 1803-13.
[http://dx.doi.org/10.1056/NEJMoa1510665] [PMID: 26406148]
[97]
Hudes G, Carducci M, Tomczak P, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356(22): 2271-81.
[http://dx.doi.org/10.1056/NEJMoa066838] [PMID: 17538086]
[98]
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403(6769): 503-11.
[http://dx.doi.org/10.1038/35000501] [PMID: 10676951]
[99]
Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100(17): 9991-6.
[http://dx.doi.org/10.1073/pnas.1732008100] [PMID: 12900505]
[100]
Castillo RR, Colilla M, Vallet-Regí M. Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer. Expert Opin Drug Deliv 2017; 14(2): 229-43.
[http://dx.doi.org/10.1080/17425247.2016.1211637] [PMID: 27402029]
[101]
Kim H, Wang Y. Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors United States patent US Patent 8,906,374. 2014.
[102]
Wang J, Sun J, Liu LN, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med 2019; 25(4): 656-66.
[http://dx.doi.org/10.1038/s41591-019-0374-x] [PMID: 30833750]

Rights & Permissions Print Cite
Article Metrics
7
© 2024 Bentham Science Publishers | Privacy Policy